No abstract available.
Bile* ; Carcinoembryonic Antigen* ; Gallbladder* ; Mesenteric Veins*

Poor control of bowel movement in some bed-ridden patients with various causes such as stroke or spinal cord injury which causes fecal leakage and diarrhea, increases the risk of perianal excoriation, bed sores and is a burden on caregivers. PURPOSE: To evaluate the efficacy of fecal evacuation, prevention and treatment of skin complications in intractable diarrhea patients employing a new device. METHODS: A continent anal plug (CAP: US Patent No. 5,569,216: Join Ent. Seoul, Korea) comprises an inner balloon surrounded by an external balloon both of which are mounted on a silicone tube containing a pair of air passages and an enema fluid inlet. The tube is secured in place in the rectum by the inflatable external balloon and is designed to drain fecal matter through a thin collapsible hose situated in the anal canal. Thirty two patients (21 male, median age 61 years, range; 28~76) were evaluated after fully informed consent. Median duration (range) was 12 (3~37) days. RESULTS: CAP evacuated efficiently in those with loose or watery stools who only required once daily irrigation or not. Skin excoriations improved in 3~7 days. Minimal leakage was seen around the anus. There was no anorectal mucosal injury noted over 37 days. Conclusions: The CAP was an efficient method of treating patients with loss of bowel control and incontinence because it enabled controlled fecal evacuation and helped reduction of skin complications without causing anorectal mucosal injury.
Anal Canal ; Bays ; Caregivers ; Diarrhea* ; Enema ; Humans ; Informed Consent ; Male ; Pressure Ulcer ; Rectum ; Seoul ; Silicones ; Skin ; Spinal Cord Injuries ; Stroke

BACKGROUND: Panel reactive antibody (PRA) test is important in that it could minimize the errorneous report of HLA crossmatch in emergent situation and be used as a information on nationwide organ sharing. However, only a few laboratories manage to do this test by home-ade tray. This study was intended to resolve the cause of discrepancy between EIA and AHG-DC which would be encountered when supplement AHG-DC was tested for EIA positive samples. METHODS: Reactivity of Lambda Antigen Tray class I and class II mixed (LAT-, One Lambda, CA, USA) was evaluated to 23 specimens which had been positive in AHG phase of HLA crossmatch. All the samples for PRA were tested by EIA screening kit primarily and then AHG-DC was applied only in EIA positive samples. Samples showing discrepant results between two tests were further evaluated by EIA identification panel, platelet absorption test, dithiothreitol (DTT) treatment, and HLA crossmatch (AHG-DC and flowcytometry) with lymphocytes having antigen specificity reactive to antibodies identified by EIA kit. RESULTS: Of 23 samples, 21 (91.3%) showed strong reactivity to EIA and remaining 2 were confirmed to have IgM type alloantibodies. Of 92 samples for PRA, 22 (23.9%) were positive in anti-LA class I. 10 of 22 samples with positive EIA showed negative results by AHG-DC. While three of them were identified of their antibody specificity, of which 2 samples confirmed to have CYNAP (cytotoxicity negative, adsorption positive) antibodies and one sample to be nonspecific reaction to class I antigens, remaining 7 samples were negative to all the wells of EIA identification (id.) kit. Signal/cut-ff (S/C) of all three samples reactive to EIA id. kit were more than 1.75. CONCLUSIONS: HLA antibody screening by EIA from transplant candidate is considered to be appropriate in that EIA could detect IgG anti-LA of all tested sera and CYNAP antibodies as well. It needs further study with larger number of samples whether S/C of EIA would be informative in cases showing EIA positive/ AHG-DC negative.
Absorption ; Adsorption ; Antibodies ; Antibody Specificity ; Blood Platelets ; Dithiothreitol ; Histocompatibility Antigens Class I ; Immunoenzyme Techniques* ; Immunoglobulin G ; Immunoglobulin M ; Isoantibodies ; Lymphocytes ; Mass Screening ; Sensitivity and Specificity

BACKGROUND: Panel reactive antibody (PRA) test is important in that it could minimize the errorneous report of HLA crossmatch in emergent situation and be used as a information on nationwide organ sharing. However, only a few laboratories manage to do this test by home-ade tray. This study was intended to resolve the cause of discrepancy between EIA and AHG-DC which would be encountered when supplement AHG-DC was tested for EIA positive samples. METHODS: Reactivity of Lambda Antigen Tray class I and class II mixed (LAT-, One Lambda, CA, USA) was evaluated to 23 specimens which had been positive in AHG phase of HLA crossmatch. All the samples for PRA were tested by EIA screening kit primarily and then AHG-DC was applied only in EIA positive samples. Samples showing discrepant results between two tests were further evaluated by EIA identification panel, platelet absorption test, dithiothreitol (DTT) treatment, and HLA crossmatch (AHG-DC and flowcytometry) with lymphocytes having antigen specificity reactive to antibodies identified by EIA kit. RESULTS: Of 23 samples, 21 (91.3%) showed strong reactivity to EIA and remaining 2 were confirmed to have IgM type alloantibodies. Of 92 samples for PRA, 22 (23.9%) were positive in anti-LA class I. 10 of 22 samples with positive EIA showed negative results by AHG-DC. While three of them were identified of their antibody specificity, of which 2 samples confirmed to have CYNAP (cytotoxicity negative, adsorption positive) antibodies and one sample to be nonspecific reaction to class I antigens, remaining 7 samples were negative to all the wells of EIA identification (id.) kit. Signal/cut-ff (S/C) of all three samples reactive to EIA id. kit were more than 1.75. CONCLUSIONS: HLA antibody screening by EIA from transplant candidate is considered to be appropriate in that EIA could detect IgG anti-LA of all tested sera and CYNAP antibodies as well. It needs further study with larger number of samples whether S/C of EIA would be informative in cases showing EIA positive/ AHG-DC negative.
Absorption ; Adsorption ; Antibodies ; Antibody Specificity ; Blood Platelets ; Dithiothreitol ; Histocompatibility Antigens Class I ; Immunoenzyme Techniques* ; Immunoglobulin G ; Immunoglobulin M ; Isoantibodies ; Lymphocytes ; Mass Screening ; Sensitivity and Specificity

The common bile duct normally enters the posteromedial aspect of the second part of the duodenum. However, anomalous drainage of the common bile duct into the stomach, pyloric channel, duodenal bulb and fourth portion of the duodenum has been reported in the literature. An anomalous pancreatic duct, with ectopic drainage of the common bile duct, is particularly rare. Herein, we report the case of a 69-year-old woman who showed pancreatic ductal variation and anomalous drainage of the common bile duct into the duodenal bulb. The patient required a cholecystectomy and choledochoenteric anastomosis to relieve the obstructive jaundice and abdominal pain.
Abdominal Pain ; Aged ; Cholecystectomy ; Common Bile Duct* ; Drainage* ; Duodenum ; Female ; Humans ; Jaundice, Obstructive ; Pancreatic Ducts* ; Stomach

BACKGROUND: The purpose of this study was to evaluate the usefulness of the pleural fluid carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1) tumor markers as complementary tools for the diagnosis of malignant pleural effusions. PATIENTS AND METHODS: The levels of pleural and serum CEA and CYFRA 21-1 were prospectively assayed in 222 patients with pleural effusions (150 benign effusions, 57 bronchogenic carcinomas and 15 metastatic carcinomas). RESULTS: The levels of pleural fluid CEA and CYFRA 21-1 in the malignant effusions were significantly higher than those in the benign effusions. With a specificity of 95%, the cut off values for the CEA and CYFRA 21-1 in pleural effusions were 5 and 89 ng/ml, respectively. The diagnostic sensitivities of the pleural fluid CEA and CYFRA 21-1 in malignant effusions were 72 and 54%, respectively, whereas using a combination of the two, the sensitivity increased to 87% (p<0.05). CONCLUSIONS : These findings suggest that a combination of the pleural fluid CEA and CYFRA 21-1 in pleural effusions can be useful in the diagnosis of malignant pleural effusions.
Carcinoembryonic Antigen ; Carcinoma, Bronchogenic ; Diagnosis ; Humans ; Keratins ; Pleural Effusion ; Pleural Effusion, Malignant* ; Prospective Studies ; Biomarkers, Tumor

Purpose: Development of malignancy is one of the key issues in the renal transplant recipients after long term follow up. Methods: We reviewed our renal transplant registry for the incidence of de novo malignancy after renal transplantation. Results: Among the 1006 renal transplant recipients from July 1969 until January 2006, 47 cases of de novo malignancy developed in 43 patients: stomach cancer (7 cases), Kaposi's sarcoma (6), post-transplantation lymphoproliferative disorder (PTLD, 7), primary liver cancer (4), thyroid cancer (3), skin cancer (4), colon cancer (3),), renal cell carcinoma (2), bladder cancer (2), anal cancer (2), sarcoma (3) and one malignancy case from conjunctiva, pancreas, uterine cervix, and tongue, respectively. Mean age at the time of diagnosis of cancer was 45.8+/-12.0 years (mean+/-standard deviation). The cancer diagnosis was made at 97.1+/-73.6 months after the renal transplantation. We have high prevalence of cancers with suspected viral etiology - i.e., Kaposi's sarcoma, PTLD, primary liver cancer and uterine cervix cancer. Conclusion: Careful surveillance of malignancy in renal allograft recipients is highly recommended.
Allografts ; Anus Neoplasms ; Carcinoma, Renal Cell ; Cervix Uteri ; Colonic Neoplasms ; Conjunctiva ; Diagnosis ; Female ; Follow-Up Studies ; Humans ; Incidence ; Kidney Transplantation* ; Kidney* ; Liver Neoplasms ; Lymphoproliferative Disorders ; Pancreas ; Prevalence ; Sarcoma ; Sarcoma, Kaposi ; Skin Neoplasms ; Stomach Neoplasms ; Thyroid Neoplasms ; Tongue ; Transplantation ; Urinary Bladder Neoplasms

Kabuki syndrome is characterized by peculiar facial features, developmental delay, and mental retardation. Congenital hepatic abnormalities in Kabuki syndrome patients have been sporadically reported in the literature and consist of extrahepatic biliary atresia, neonatal sclerosing cholangitis, and transient neonatal cholestasis. We report here a case of congenital hepatic fibrosis in a patient with Kabuki syndrome. To our knowledge, only one case of congenital hepatic fibrosis has been reported in the setting of Kabuki syndrome.
Abnormalities, Multiple ; Biliary Atresia ; Cholangitis, Sclerosing ; Cholestasis ; Face ; Fibrosis ; Hematologic Diseases ; Humans ; Intellectual Disability ; Vestibular Diseases

PURPOSE: Hepatic allografts from donors with hepatitis B core antibody have been demonstrated to transmit hepatitis B virus (HBV) infection to recipients after liver transplantation (LT). The efficacy of hepatitis B immune globulin (HBIg) to prevent de novo hepatitis B was investigated by comparing active immunization in the early phase to HBIg monotherapy in the late phase of pediatric liver transplants at Samsung Medical Center. METHODS: Among pediatric liver transplants, from May, 1996 to June, 2002, 15 recipients who were hepatitis B surface antigen (HBsAg) (-) received an allograft from a donor with hepatitis B core antibody (HBcAb) (+). Except two who died from unrelated causes, eleven of 13 recipients were HBsAb (+), and 2 were naive (HBsAb(-), HBcAb(-)). All patients were vaccinated for HBV before LT. In the early phase (January, 1997~November, 1997, 3 patients), HBsAb (+) recipients received booster vaccination after LT. In the late phase (December, 1997~, 10 patients), all recipients were given booster vaccination and received HBIg therapy in order to maintain HBsAb titer greater than 200 IU/L. Lamivudine was given in one case because of severe side effect of HBIg. We retrospectively analyzed the effect of the preventive therapy for de novo hepatitis B through medical records. RESULTS: De novo hepatitis B developed in three of 13 recipients (23.1%). All of 3 patients who received active immunization in the early phase became HBsAg (+) at 7~19 months after transplantation. One of them was naive before LT and the other two were HBsAb (+). All of 10 recipients who were given HBIg in the late phase remained HBsAg (-) at 7~55 months' follow-up. CONCLUSION: Passive immunization with HBIg was effective for prevention of de novo hepatitis B in HBsAg (-) recipients of hepatic allografts from HBcAb (+) donors.
Allografts ; Follow-Up Studies ; Hepatitis B Surface Antigens ; Hepatitis B virus ; Hepatitis B* ; Hepatitis* ; Humans ; Immunization, Passive ; Lamivudine ; Liver Transplantation* ; Liver* ; Medical Records ; Retrospective Studies ; Tissue Donors ; Vaccination

BACKGROUND: To report the results of an arthroscopic percutaneous repair technique for partial-thickness tears of the anterosuperior cuff combined with a biceps lesion. METHODS: The inclusion criteria were evidence of the upper subscapularis tendon tear and an articular side partial-thickness tear of the supraspinatus tendon, degeneration of the biceps long head or degenerative superior labrum anterior-posterior, above lesions treated by arthroscopic percutaneous repair, and follow-up duration > 24 months after the operation. American Shoulder and Elbow Surgeons (ASES) score, constant score, the pain level on a visual analogue scale, ranges of motion and strength were assessed. RESULTS: The mean (+/- standard deviation) age of the 20 enrolled patients was 56.0 +/- 7.7 years. The forward flexion strength increased from 26.3 +/- 6.7 Nm preoperatively to 38.9 +/- 5.1 Nm at final follow-up. External and internal rotation strength was also significantly increased (14.2 +/- 1.7 to 19.1 +/- 3.03 Nm, 12.3 +/- 3.2 to 18.1 +/- 2.8 Nm, respectively). Significant improvement was observed in ASES and constant scores at 3 months, 1 year and the time of final follow-up when compared with preoperative scores (p < 0.001). The mean subjective shoulder value was 86% (range, 78% to 97%). CONCLUSIONS: The implementation of complete rotator cuff repair with concomitant tenodesis of the biceps long head using arthroscopic percutaneous repair achieved full recovery of normal rotator cuff function, maximum therapeutic efficacy, and patient satisfaction.
Aged ; Arthroscopy/adverse effects/*methods ; Female ; Follow-Up Studies ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Muscle, Skeletal/*injuries/*surgery ; Pain Measurement ; Range of Motion, Articular ; Rotator Cuff/*injuries/pathology/*surgery ; Statistics, Nonparametric ; Treatment Outcome